Session Name: Comorbid Conditions – When to Refer and When Not_Part 1: 2024 Series

Date: 06/1/2024

We appreciate your time and effort in participating in this CME Sessional Evaluation. This evaluation is a pipeline to bring your voice to the leadership, instructors, and CME team. We value your voice and try our best to improve the quality of future activities.

 

*
*
Did/Will you use this information for specific patient(s)?
What patient/health care problem recently challenged you, and you wish you knew more about? Feedback will help formulate ideas for future Lunch and Learn topics.
Comments and Feedback on the learning experience, content, procedure, and instructors, etc. in this session.
As a result of my participation in this activity, I am better able to... 4 - Strongly Agree 3- Agree 2 - Somewhat Disagree 1- Strongly disagree
1234
Review the updated incidence of obesity of children and adults in the US​
Identify one complication of obesity on a child’s health
Utilizing NEW Kids Program for optimization of health and subspecialty care at Children’s Wisconsin
Role of the PCP in Obesity Assessment​
When to Refer​ Patients
Pharmacotherapy for Obesity management
Dyslipidemia – Prevalence, Screening, Treatment
Elevated BP/Hypertension – Prevalence, Screening, Treatment
Healthy Hearts Clinic Overview
Increase knowledge of pediatric steatotic liver disease​: Epidemiology, Pathophysiology​, Workup​, Surveillance for progression​
Highlight recent therapies for steatotic liver disease
The following speaker(s) demonstrated experiential knowledge of the topic 4 - Strongly Agree 3- Agree 2 - Somewhat Disagree 1- Strongly Disagree
1234
Denise M. Kilway, DNP, RN, APNP​
Elizabeth Dabrowski, MD​
Dan Beacher, MD
Cara Mack, MD​
Choose the option that best fits your evaluation of this activity: 4 - Strongly Agree 3- Agree 2 - Somewhat Disagree 1- Strongly Disagree
1234
The content provided a fair and balanced coverage of the topic
The content was free of commercial bias